Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group.
Kelly D GetzTodd A AlonzoLillian SungSoheil MeshinchiRobert B GerbingSusana RaimondiBetsy HirschMichael LokenLisa Eidenschink BrodersenSamir KahwashJohn ChoiE Anders KolbAlan GamisRichard AplencPublished in: Pediatric blood & cancer (2021)
Our results support de-escalation of cytarabine exposure through the elimination of a fifth chemotherapy course only for LR-AML patients who have both favorable cytogenetic/molecular features and negative MRD after the first induction cycle.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- high dose
- palliative care
- young adults
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- open label
- acute lymphoblastic leukemia
- locally advanced
- radiation therapy
- patient reported